about
Impact on sexual function of holmium laser enucleation versus transurethral resection of the prostate: results of a prospective, 2-center, randomized trial.Nerve-sparing radical retropubic prostatectomy in patients previously submitted to holmium laser enucleation of the prostate for bladder outlet obstruction due to benign prostatic enlargement.Holmium laser enucleation of the prostate and holmium laser ablation of the prostate: indications and outcome.Detection and diagnosis of prostate cancer: what's new.Optimizing postoperative sexual function after radical prostatectomyExternal validation of a nomogram for prediction of side-specific extracapsular extension at robotic radical prostatectomy.Prophylaxis of erectile function after radical prostatectomy with phosphodiesterase type 5 inhibitors.Surgery and erectile dysfunction.Balancing continence function and oncological outcomes during robot-assisted radical prostatectomy (RARP).Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection.Fifteen-year single-centre experience with three different surgical procedures of nerve-sparing cystectomy in selected organ-confined bladder cancer patients.Initial biopsy outcome prediction--head-to-head comparison of a logistic regression-based nomogram versus artificial neural network.Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy.Trans-rectal versus trans-perineal saturation rebiopsy of the prostate: is there a difference in cancer detection rate?Non-surgically related causes of erectile dysfunction after bilateral nerve-sparing radical prostatectomy.Preoperative Favorable Characteristics in Bladder Cancer Patients Cannot Substitute the Necessity of Extended Lymphadenectomy During Radical Cystectomy: A Sensitivity Curve Analysis.Lymphatic spread of nodal metastases in high-risk prostate cancer: The ascending pathway from the pelvis to the retroperitoneum.Postoperative phosphodiesterase type 5 inhibitor administration increases the rate of urinary continence recovery after bilateral nerve-sparing radical prostatectomy.When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool.Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.Extent of lymph node dissection at nephrectomy affects cancer-specific survival and metastatic progression in specific sub-categories of patients with renal cell carcinoma (RCC).Age-adjusted validation of the most stringent criteria for active surveillance in low-risk prostate cancer patients.Nerve-sparing approach during radical prostatectomy is strongly associated with the rate of postoperative urinary continence recovery.Serum sex steroids depict a nonlinear u-shaped association with high-risk prostate cancer at radical prostatectomy.Prostate cancer-specific survival in men treated with hormonal therapy after failure of radical prostatectomy.Preoperative erectile function represents a significant predictor of postoperative urinary continence recovery in patients treated with bilateral nerve sparing radical prostatectomy.Postoperative orgasmic function increases over time in patients undergoing nerve-sparing radical prostatectomy.Sperm banking is of key importance in patients with prostate cancer.Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis.Unsuccessful investigation of preoperative sexual health issues in the prostate cancer "couple": results of a real-life psychometric survey at a major tertiary academic center.Assessing the most accurate formula to predict the risk of lymph node metastases from prostate cancer in contemporary patients treated with radical prostatectomy and extended pelvic lymph node dissection.Mortality at 120 days after prostatic biopsy: a population-based study of 22,175 men.Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer.Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis.The number of cores taken in patients diagnosed with a single microfocus at initial biopsy is a major predictor of insignificant prostate cancer.Menstrual cycle-related changes in circulating androgens in healthy women with self-reported normal sexual function.Influence of obesity on tumour volume in patients with prostate cancer.Role of urinary cathepsin B and L in the detection of bladder urothelial cell carcinoma.A novel tool to assess the risk of urinary incontinence after nerve-sparing radical prostatectomy.Prostate volume and adverse prostate cancer features: fact not artifact.
P50
Q33239169-8944C633-FB29-45AC-BE8C-29023CE0B1DCQ33292095-64C2B8BA-3271-4E35-A643-F146210C580BQ33389788-CBF2AAF1-7315-4C2D-93C8-BAFB79B00B2BQ36350425-9817AC31-2FEB-4BBF-BA41-E72CE7C60AAEQ36379338-2B0FF192-092E-4F1F-94EB-2BFD5E05A067Q37016132-F84D909E-DDA4-48DE-8A00-259920F8915CQ37622389-21B358A1-090D-4B9E-94B4-9D62902ACA87Q37803313-6B3147B7-EB5A-4CE6-8284-8CF69605678CQ37932067-E2510B68-2B01-451A-9FDB-05CD818D4EDBQ37958294-416E2A4D-D1F3-44F2-96E0-B17246D03373Q39061810-74824A41-15DF-4DBF-B619-3CEC1A05F665Q39767367-E45C6F2A-C025-4546-A47B-9C371BBD91ADQ39898872-86D10373-EFBD-438D-A0AD-0DC5CC2956E4Q39961504-EFEC80C8-51C8-4BD0-BEE2-74E2B0EC6B68Q40013435-66EA3F54-9953-4692-9CC2-4B58F2E1D521Q40194329-8BB0D826-EE9E-4186-B55E-CA68E19641B2Q42599403-09ED409C-1F39-4247-A64A-F6B8D91E0E9BQ42667696-3E345D24-E5A1-4D47-9B6B-2F4F96A29F9DQ43207980-C0A77789-1917-487E-8003-10C3B6F4335CQ43636349-BA587E2A-93C7-41BE-BD05-DD3338E0E129Q43733514-C5AA03AC-457E-4B58-BE8B-6D4510A98A0BQ43871998-4619DF11-2D69-4CF5-8081-DBDB0423E9C1Q44749931-53A15FD9-C99B-4EA6-A805-DBCE696440CFQ44908788-0056CFEE-9914-41D8-ABFC-6E73BE747109Q44925172-86363A34-0FD7-4D97-B621-8317AB8026FEQ45158639-D0FAA1C0-7736-4FB6-9699-D809A46C7CB6Q45213932-7F72AA9F-B309-4A47-8A0A-49809A919B57Q45216415-3F6D7D07-1C02-4BA6-95B4-AF1608007E79Q45376750-70B902DD-67BB-4343-BE17-C8418168B271Q45719138-988B18CD-EB1B-4F7D-8918-17526D8ADBDFQ46053699-CFB14198-DD8F-4A15-B54D-51DAD4EF164CQ46063759-21D67C12-797B-449B-BBAE-A670205EDEABQ46086036-46619C6F-CD0D-4448-AC98-BAFAFE7005F8Q46313775-4D44DADD-3B39-4B2C-A2AB-2F29A77A9139Q46468428-4F629EF7-6706-4F0B-8A75-04DD0BE5137AQ46678966-DB820D58-719D-418B-91CE-2372F7D9B9BAQ46770186-B9B42A2C-E379-4455-B0BE-753BD5BDBEB2Q46852739-8A227A2A-6B52-437A-A6B0-0CAD8F6EF143Q46904024-681D18A3-221F-410C-9F1F-64C634250B6FQ46904796-77EEA7A2-1F70-414E-9240-CC4673F0E65B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Andrea Gallina
@ast
Andrea Gallina
@en
Andrea Gallina
@es
Andrea Gallina
@nl
Andrea Gallina
@sl
type
label
Andrea Gallina
@ast
Andrea Gallina
@en
Andrea Gallina
@es
Andrea Gallina
@nl
Andrea Gallina
@sl
prefLabel
Andrea Gallina
@ast
Andrea Gallina
@en
Andrea Gallina
@es
Andrea Gallina
@nl
Andrea Gallina
@sl
P106
P1153
9234389500
P31
P496
0000-0002-4540-9569